What Is Strategy in Biotechnology?

Why the Next Decade Will Be Defined by Platforms, Partnerships, and Learning

Strategy may be the most frequently used word in business.

It is also one of the most misunderstood.

In biotechnology, we often hear executives describe their strategy as becoming a leader in oncology, adopting artificial intelligence, expanding into cell therapy, or building a larger pipeline.

These are ambitions.

They are not strategies.

A strategy is not simply deciding where you want to compete.

It is deciding how you will create value in a way that competitors cannot easily replicate.

Michael Porter articulated this idea decades ago, arguing that sustainable competitive advantage comes from making deliberate choices. Companies outperform competitors by doing different things or by doing similar things differently. Just as importantly, strategy requires deciding what not to pursue.

Those principles remain as relevant today as ever.

Yet biotechnology is changing in ways that suggest strategy itself is evolving.

Science Is No Longer the Limiting Factor

For much of the industry's history, scientific discovery was the primary bottleneck.

Today, remarkable science exists almost everywhere.

Groundbreaking discoveries emerge daily from universities.

Venture-backed biotechnology companies continue to push the boundaries of biology.

Artificial intelligence companies are entering drug discovery.

Academic medical centers are generating unprecedented biological insight.

Innovation has become widely distributed.

The competitive question is no longer who discovers the most interesting science.

It is who recognizes, integrates, and commercializes that science most effectively.

Strategy Is Becoming an Integration Problem

Few organizations possess every capability required to succeed.

Drug discovery increasingly depends on integrating disciplines that historically evolved independently.

Artificial intelligence.

Structural biology.

Genomics.

Medicinal chemistry.

Protein engineering.

Clinical development.

Manufacturing.

Companion diagnostics.

Real-world evidence.

No single organization can realistically lead every field simultaneously.

The most successful companies will not necessarily own every capability.

They will know how to orchestrate them.

External Innovation Is No Longer Optional

This is why external innovation has become central to corporate strategy.

Historically, business development often focused on acquiring molecules or licensing therapeutic assets.

Today's partnerships increasingly revolve around capabilities.

Discovery platforms.

Artificial intelligence.

Manufacturing technologies.

Gene editing.

Target identification.

Novel delivery systems.

The objective is no longer simply expanding a pipeline.

It is strengthening the organization's ability to innovate repeatedly.

External innovation has evolved from a transactional function into a strategic capability.

Platform Thinking Changes Everything

Another important shift is occurring.

Products create revenue.

Platforms create future opportunities.

An antibody discovery platform improves with every campaign.

An AI model learns from every experiment.

A gene editing platform expands into new indications.

A manufacturing platform becomes more efficient with every production run.

Platform companies accumulate knowledge.

Knowledge compounds.

That compounding effect creates a form of competitive advantage that traditional strategic frameworks only partially anticipated.

Learning Is Becoming the New Competitive Advantage

Perhaps the greatest strategic shift occurring today is that organizations increasingly compete based on how quickly they learn.

Artificial intelligence accelerates learning.

High-throughput experimentation accelerates learning.

Digital pathology accelerates learning.

Human genetics accelerates learning.

Every experiment creates new data.

Every partnership expands scientific understanding.

Every clinical trial informs future discovery.

Organizations that continuously improve their decision-making systems will likely outperform those focused solely on individual products.

Strategy in the AI Era

Artificial intelligence does not eliminate the need for strategy.

It makes strategy even more important.

As computational tools lower barriers to discovery, differentiation will increasingly come from asking better scientific questions, building stronger partnerships, integrating diverse technologies, and making better portfolio decisions.

Algorithms may generate possibilities.

Strategy determines which possibilities deserve investment.

In many ways, biotechnology is becoming a learning industry.

Looking Ahead

The biotechnology companies that define the next decade will not simply have the most promising pipelines.

They will build the strongest innovation ecosystems.

They will understand where internal capabilities create differentiation and where external partnerships accelerate progress.

They will recognize that platform technologies often generate more long-term value than individual products.

Most importantly, they will understand that strategy is no longer just about positioning.

It is about building organizations that continuously learn, adapt, and integrate scientific innovation wherever it emerges.

Michael Porter reminded us that strategy is about making choices.

In biotechnology, those choices are becoming more complex than ever before.

Knowing what to build.

Knowing what to partner.

Knowing what to license.

Knowing what to acquire.

And perhaps most importantly, knowing what not to pursue.

Because in an industry where scientific possibilities are expanding exponentially, sustainable competitive advantage will belong not to those who try to do everything, but to those who make the clearest strategic choices and build the strongest systems for turning innovation into impact.